KCT0002374已完成未知
A randomized, double-blind, placebo-controlled, multi-center pilot clinical trial to evaluate the efficacy and safety of Dangguixu-san(Carecon capsule) on ankle sprain
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) People over the age of 19 who sprained lateral ankle joint(Grade ?or?) within 72 hours
- •2) People who have sufficient cognitive function and have voluntarily signed the agreement
排除标准
- •1) Ankle fracture on X-ray
- •2) Grade? or severe damage which requires surgery
- •3) Previous ankle fracture on same injured joint within 1 year
- •4) Severe diseases (cancer, kidney disease, liver disease, neurological disease, blood coagulation disease, dementia)
- •5) Neurological disorder on damaged lower extremity including motor disturbance or sensory loss
- •6) Pregnant or possible pregnant woman, lactating woman
- •7) Patient who took NSAID, painkiller, steroids to control pain after injury (exception: use of pain relief patch on the screening day)
- •8) Impaired liver function (ALT over 80 IU/L), impaired kidney function (Creatinine over 2 mg/dl)
- •9) Patient who are deemed to be unsuitable due to the result of past tests or has historical history which may negatively affect the test
- •10) Patient who has genetic disorder such as galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption
- •11) Patients with allergic reaction to clinical trial drug ingredients
- •12) Patients who participated in other clinical trials within 4 weeks or have participating in another clinical trials
研究者
相似试验
进行中（未招募）
1 期
Study on the safety of the drug runcaciguat and how well it works when given at the highest dose as tolerated by the individual patient whose kidneys are not working properly and suffering at the same time from a disease of the heart and the blood vessels and high blood sugarTreatment of cardiovascular and renal disease in patients with chronic kidney diseaseMedDRA version: 21.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 20.0Level: PTClassification code 10001580Term: AlbuminuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2019-003297-53-ESBayer AG432
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of licarbazepine 750-2500 mg/d combined with risperidone in the treatment of manic episodes of bipolar I disorder over 6 weeksBipolar I disorder, manic and mixed episodesEUCTR2004-000113-18-HUovartis Hungaria Kft.430
进行中（未招募）
1 期
Phase 2b dose-ranging study of ALX-0171 in infants and young children hospitalized for RSV lower respiratory tract infectioRSV lower respiratory tract infectionMedDRA version: 20.1Level: PTClassification code 10061603Term: Respiratory syncytial virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2016-001651-49-SKAblynx NV180
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapyDiffuse Large B-Cell LymphomaMedDRA version: 19.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-000498-40-HUovartis Pharma Services AG487
进行中（未招募）
1 期
Safety and efficacy study in patients with moderate to severe nail psoriasisModerate to severe nail psoriasisMedDRA version: 18.0Level: PTClassification code 10028703Term: Nail psoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2012-005413-40-BEovartis Pharma Services AG195